Skip to main content

Market Overview

Salix Receives FDA CDRH Approval for Additional Injection Techniques for Deflux

Share:

Salix Pharmaceuticals (NASDAQ: SLXP) today announced that The
Center for Devices and Radiological Health (CDRH) of the Food and Drug
Administration (FDA) has approved the Deflux® premarket
approval (PMA) supplement, which requested approval of labeling changes
to add two additional techniques for injection, a single intra-ureteric
injection (HIT procedure) and a double (proximal and distal)
intra-ureteric injection (Double-HIT procedure).

“Deflux® has always been an effective, minimally invasive
option for children suffering from vesicoureteral reflux grades II-IV.
This approval and update to the Deflux® labeling provides
pediatric urologists even more confidence to offer Deflux to families,”
said Carolyn Logan, President and CEO of Salix.

See full press release

 

Related Articles (SLXP)

View Comments and Join the Discussion!

Posted-In: News Guidance Financing Asset Sales FDA Management Global

Need corporate guidance data?
Click here to see licensing options.
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com